Oric Pharmaceuticals announces agreement with Cancer Research UK

ORIC•2026-10-05

Cancer Research UK will fully fund and execute early clinical development of ORIC-259, a potential first-in-class CIP2A-targeted therapy; Oric retains an option to reacquire the rights after Phase 1/2 data.

1. Development agreement

Oric Pharmaceuticals announced an agreement with Cancer Research UK to advance ORIC-259 into clinical development. Cancer Research UK will fully fund and execute early clinical development, while Oric retains an option to reacquire the rights after Phase 1/2 data.

Oric Pharmaceuticals announces agreement with Cancer Research UK

1. Development agreement

Related News

Ten Holdings names Everest Advisors’ Ian Lawson interim CFO

Fortis to host conference call, webcast on Q3 2026 results and five-year capital outlook

Apollo estimates Q3 alternative net investment income at about $375 million pre-tax

Zcash ETF adds Anchorage Digital as additional ZEC custodian

UBS declares coupon payments on 12 ETRACS exchange-traded notes